Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434109 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
A Phase 2 study of Neuroendocrine Tumor and Islet Cell Tumor, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00434109 is a Phase 2 study of Neuroendocrine Tumor and Islet Cell Tumor that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 39 participants, below the 138-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00434109, a Phase 2 study of Neuroendocrine Tumor and Islet Cell Tumor, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
Conditions Studied
Interventions
- DRUG Sunitinib malate
- PROCEDURE Hepatic Artery Embolizations
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00434109
The ClinicalTrials.gov registry entry for NCT00434109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (72% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumor appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib malate is the first listed.
NCT00434109 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00434109 about?
NCT00434109 is a clinical study titled "Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization". The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
What is the current status of trial NCT00434109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2006-11. Estimated completion is 2012-02.
What conditions does trial NCT00434109 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Islet Cell Tumor.
What interventions are being tested in trial NCT00434109?
The interventions under investigation include: Sunitinib malate (DRUG), Hepatic Artery Embolizations (PROCEDURE).
Who is sponsoring clinical trial NCT00434109?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00434109 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
COMPLETED · Phase 2
-
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
RECRUITING · Early Phase 1
-
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
RECRUITING · NA
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.